Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing ...

Science rarely hands us plot twists this dramatic—where two of the most feared diseases of our time, cancer and Alzheimer’s, ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for ...

Amyloid beta and tau proteins compete for the same binding sites on microtubules in neurons, suggesting that displacement of ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD), reports a new study at Columbia ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...

Omega fatty acids may help protect women from Alzheimer’s disease, revealing why more women are diagnosed, according to a study from King’s College London and Queen Mary University of London. The ...